论文部分内容阅读
目的:探索阿立派唑与奋乃静对首发精神分裂症患者认知功能影响的对照.方法:选取124例首发精神分裂症患者,将患者分为阿立哌唑组和奋乃静组.奋乃静组应用奋乃静实施治疗,阿立哌唑组则应用阿立哌唑实施治疗.评价两组的治疗效果(用阳性和阴性症状量表PANSS),并对两组的认知功能进行对比(用临床记忆量表CMS和韦氏成人智力量表WAIS-RC).结果:经治疗,两组患者在疗效上相近,组间对比差异无统计学意义(P>0.05).而在认知功能指标上,阿立哌唑组跟奋乃静组相比有明显优势,组间对比差异有统计学意义(P 0.05). And on the index of cognitive function, aripiprazole group and perphenazine fluphenazine group has obvious advantages compared. The differences between the two groups has statistical significance (P < 0.05).Conclusion Perphenazine and aripiprazole on first-episode split patients have the effect, but compared with perphenazine, aripiprazole is more conducive to improving the cognitive function of patients, worthy of promotion.